Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. The Dow Jones Industrial Average ( ^DJI) is trading down 19.0 points (-0.1%) at 15,196 as of Wednesday, May 15, 2013, 10:35 a.m. ET. During this time, 122.6 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 596.6 million. The NYSE advances/declines ratio sits at 1,188 issues advancing vs. 1,637 declining with 145 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be Procter & Gamble (NYSE: PG), which is sporting a $1.14 gain (+1.4%) bringing the stock to $80.61. Volume for Procter & Gamble currently sits at 2.8 million shares traded vs. an average daily trading volume of nine million shares. Procter & Gamble has a market cap of $215.4 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 17.1% year to date as of Tuesday's close. The stock's dividend yield sits at 3.1%. The Procter & Gamble Company, together with its subsidiaries, engages in the manufacture and sale of a range of branded consumer packaged goods. The company operates in five segments: Beauty, Grooming, Health Care, Fabric Care and Home Care, and Baby Care and Family Care. The company has a P/E ratio of 19.8, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Procter & Gamble as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, increase in net income, good cash flow from operations and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.